Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02175225 · ClinicalTrials.gov registry record · Phase 2
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 294
- Enrollment target
NCT02175225: Completed Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
NCT02175225 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 294 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (121% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02175225, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 294 participants
- Enrollment target
Study Summary
The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.
Primary Outcome
The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome.
Interventions
- DRUG Deferoxamine Mesylate
- DRUG Placebo (for Deferoxamine Mesylate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 2 |
What the finished NCT02175225 record still lists
NCT02175225 is an interventional study that assigns participants to a tested intervention. The registered 294 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (121% higher).
The record links to 0 conditions, and to 2 interventions - of which Deferoxamine Mesylate is the first listed.
NCT02175225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02175225 about?
NCT02175225 is a clinical study titled "Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial". The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a la...
What is the current status of trial NCT02175225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 294 participants. The study started on 2014-10. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT02175225?
The interventions under investigation include: Deferoxamine Mesylate (DRUG), Placebo (for Deferoxamine Mesylate) (DRUG).
Who is sponsoring clinical trial NCT02175225?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02175225's enrollment target sits among peer trials
294 190th of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia